Electronic Journal of Liver Tumor ›› 2019, Vol. 6 ›› Issue (4): 5-8.
• Expert forum • Previous Articles Next Articles
Online:2019-12-30
Published:2020-01-19
| [1] | Torre LA, Bray F, Siegel RL , et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108. |
| [2] | European Association for the Study of The Liver, European Association for the Study of The Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma [J]. J Hepatol, 2012,56(4):908-943. |
| [3] | Demaria S, Bhardwaj N, Mcbride WH , et al. Combining radiotherapy and immunotherapy: a revived partnership[J]. Int J Radiat Oncol Biol Phys, 2005,63(3):655-666. |
| [4] | Demaria S, Ng B, Devitt ML , et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated[J]. Int J Radiat Oncol Biol Phys, 2004,58(3):862-870. |
| [5] | Frey B, Rubner Y, Wunderlich R , et al. Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies[J]. Curr Med Chem, 2012,19(12):1751-1764. |
| [6] | Lugade AA, Moran JP, Gerber SA , et al. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor[J]. 2005,174(12):7516-7523. |
| [7] | North RJ . Radiation-induced, immunologically mediated regression of an established tumor as an example of successful therapeutic immunomanipulation. Preferential elimination of suppressor T cells allows sustained production of effector T cells[J]. 1986,164(5):1652-1666. |
| [8] | Jenne CN, Kubes P . Immune surveillance by the liver[J]. Nat Immunol, 2013,14(10):996-1006. |
| [9] | Diehl L, Schurich A, Grochtmann R , et al. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance[J]. Hepatology, 2008,47(1):296-305. |
| [10] | Schildberg FA, Hegenbarth SI, Schumak B , et al. Liver sinusoidal endothelial cells veto CD8 T cell activation by antigen-presenting dendritic cells[J]. Eur J Immunol, 2008,38(4):957-967. |
| [11] | Kim HY, Park JW . Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions[J]. Therap Adv Gastroenterol, 2017,10(10):805-814. |
| [12] | Chew V, Lai L, Pan L , et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses[J]. Proc Natl Acad Sci U S A, 2017,114(29):E5900-E5909. |
| [13] | Tada F, Abe M, Hirooka M , et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Int J Oncol, 2012,41(5):1601-1609. |
| [14] | Palmer DH, Midgley RS, Mirza N , et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology, 2009,49(1):124-132. |
| [15] | El Ansary M, Mogawer S, Elhamid SA , et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol, 2013,139(1):39-48. |
| [16] | Lee JH, Lee Y, Lee M , et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Br J Cancer, 2015,113(12):1666-1676. |
| [17] | Takayama T, Sekine T, Makuuchi M , et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. The Lancet, 2000,356(9232):802-807. |
| [18] | Hui D, Qiang L, Jian W , et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma[J]. Dig Liver Dis, 2009,41(1):36-41. |
| [19] | Weng D-S, Zhou J, Zhou Q-M , et al. Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas[J]. 2008,31(1):63-71. |
| [20] | Lee JH, Lee JH, Lim YS , et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology, 2015,148(7):1383-1391. |
| [21] | Rudd CE, Taylor A, Schneider H . CD28 and CTLA-4 coreceptor expression and signal transduction[J]. Immunol Rev, 2009,229(1):12-26. |
| [22] | Fife BT, Bluestone JA . Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J]. Immunol Rev, 2008,224(1):166-182. |
| [23] | Sangro B, Gomez-Martin C, De La Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013,59(1):81-88. |
| [24] | Duffy AG, Ulahannan SV, Makorova-Rusher O , et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017,66(3):545-551. |
| [25] | El-Khoueiry AB, Sangro B, Yau T , et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017,389(10088):2492-2502. |
| [26] | Wainberg ZA, Segal NH, Jaeger D , et al. Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2017,35(15_suppl):4071-4071. |
| [27] | Zhu AX, Finn RS, Edeline J , et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018,19(7):940-952. |
| [28] | Gameiro SR, Ardiani A, Kwilas A , et al. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens[J]. Oncoimmunology, 2014,3(e28643):1-3. |
| [29] | Ma Y, Kepp O, Ghiringhelli F , et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines[J]. Semin Immunol, 2010,22(3):113-124. |
| [30] | Vanpouille-Box C, Pilones KA, Wennerberg E , et al. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment[J]. Vaccine, 2015,33(51):7415-7422. |
| [31] | Golden EB, Frances D, Pellicciotta I , et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death[J]. Oncoimmunology, 2014,3(e28518):1-12. |
| [32] | 崔佳宁, 王俊杰 . 免疫治疗联合放疗治疗晚期非小细胞肺癌的进展[J]. 现代肿瘤医学, 2018,26(15):2477-2480. |
| [33] | Thompson RF, Maity A . Radiotherapy and the tumor microenvironment: mutual influence and clinical implications[J]. Adv Exp Med Biol, 2014,772:147-165. |
| [34] | Dewan MZ, Galloway AE, Kawashima N , et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res, 2009,15(17):5379-5388. |
| [35] | Vanpouille-Box C, Alard A, Aryankalayil MJ , et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity[J]. Nat Commun, 2017,8(15618):1-15. |
| [36] | Formenti SC . Optimizing Dose Per Fraction: A New Chapter in the Story of the Abscopal Effect?[J]. Int J Radiat Oncol Biol Phys, 2017,99(3):677-679. |
| [37] | Formenti SC, Demaria S . Combining radiotherapy and cancer immunotherapy: a paradigm shift[J]. J Natl Cancer Inst, 2013,105(4):256-265. |
| [ 38 Bernstein MB, Krishnan S, Hodge JW , et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?[J]. Nat Rev Clin Oncol, 2016,13(8):516-524. | |
| [39] | Gong J, Le TQ, Massarelli E , et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination[J]. J Immunother Cancer, 2018,6(46):1-17. |
| [40] | Weichselbaum RR, Liang H, Deng L , et al. Radiotherapy and immunotherapy: a beneficial liaison?[J]. Nat Rev Clin Oncol, 2017,14(6):365-379. |
| [41] | Golden EB, Formenti SC . Is tumor (R)ejection by the immune system the "5th R" of radiobiology?[J]. Oncoimmunology, 2014,3(e28133):1-3. |
| [42] | Hiniker SM, Chen DS, Reddy S , et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy[J]. Transl Oncol, 2012,5(6):404-407. |
| [43] | Stamell EF, Wolchok JD, Gnjatic S , et al. The abscopal effect associated with a systemic anti-melanoma immune response[J]. Int J Radiat Oncol Biol Phys, 2013,85(2):293-295. |
| [44] | Postow MA, Callahan MK, Barker CA , et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. New Engl J Med, 2012,366(10):925-931. |
| [45] | Silk AW, Bassetti MF, West BT , et al. Ipilimumab and radiation therapy for melanoma brain metastases[J]. Cancer Med, 2013,2(6):899-906. |
| [46] | Karbach J, Gnjatic S, Biskamp M , et al. Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates[J]. Cancer Immunol Res, 2014,2(5):404-409. |
| [47] | Kiess AP, Wolchok JD, Barker CA , et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment[J]. Int J Radiat Oncol Biol Phys, 2015,92(2):368-375. |
| [48] | Golden EB, Chachoua A, Fenton-Kerimian MB , et al. Abscopal Responses in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated on a Phase 2 Study of Combined Radiation Therapy and Ipilimumab: Evidence for the In Situ Vaccination Hypojournal of Radiation[J]. Int J Radiat Oncol Biol Phys, 2015,93(3):S66-S67. |
| [49] | Kwon ED, Drake CG, Scher HI , et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014,15(7):700-712. |
| [50] | Roger A, Finet A, Boru B , et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients[J]. Oncoimmunology, 2018,7(e1442166):1-8. |
| [51] | Shaverdian N, Lisberg AE, Bornazyan K , et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017,18(7):895-903. |
| [52] | Antonia SJ, Villegas A, Daniel D , et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer[J]. New Engl J Med, 2017,377(20):1919-1929. |
| [53] | Wahl DR, Stenmark MH, Tao Y , et al. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J]. J Clin Oncol, 2016,34(5):452-459. |
| [54] | Ohri N, Dawson LA, Krishnan S , et al. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study[J]. J Natl Cancer Inst, 2016,108(9):1-10. |
| [55] | Kim KJ, Kim JH, Lee SJ , et al. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model[J]. Oncotarget, 2017,8(25):41242-41255. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
